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is induced in leptin-deficient (ob/ob)mouse liver and is
critical for the development of hepatic steatosis. The
present study shows that fat-specific protein 27
(Fsp27) in ob/ob liver is a direct target gene of PPARg
and can elevate hepatic triglyceride levels. FSP27 be-
longs to theCIDE family, composedofCIDEA,CIDEB,
and FSP27/CIDE C, all of which contain a conserved
CIDE-N domain. FSP27 was recently reported to be
a lipid droplet-binding protein and to promote lipid
accumulation in adipocytes. The Fsp27 gene was ex-
pressed at high levels in ob/ob liver and at markedly
lower levels in ob/ob livers lacking PPARg. Forced
expression of FSP27 by adenovirus in hepatocytes
in vitro or in vivo led to increased triglyceride levels.
Knockdown by adenovirus expressing FSP27 shRNA
resulted in lower accumulationof hepatic triglycerides
compared to control adenovirus-infected liver. Taken
together, these results indicate that FSP27 is a direct
mediator of PPARg-dependent hepatic steatosis.
INTRODUCTION
Peroxisome proliferator-activated receptor g (PPARg) belongs
to the nuclear receptor superfamily and can regulate the tran-
scription of genes in response to specific ligands. The synthetic
ligands of PPARg, thiazolidinediones, are used clinically to re-
duce insulin resistance and improve hyperglycemia associated
with type 2 diabetes (Gervois et al., 2007). PPARg is expressed
at the highest level in adipose tissue (Tontonoz et al., 1994)
and is required for the differentiation of preadipocytes to mature
adipocytes (Rosen et al., 2002). In contrast, PPARg is typically
expressed in both human and murine liver at only 10%–30% of
the levels found in adipose tissue (Tontonoz et al., 1994). How-
ever, it is expressed at markedly elevated levels in the severe
fatty liver associated with a number ofmurinemodels of diabetes
or obesity (Bedoucha et al., 2001; Memon et al., 2000).
Previously, we generated a PPARg (Pparg) liver-null mouse
on an ob/ob genetic background (ob/ob-PPARg/Cre+) using302 Cell Metabolism 7, 302–311, April 2008 ª2008 Elsevier Inc.a floxed PPARg allele and Cre recombinase under control of
the albumin promoter. The ob/ob-PPARg/Cre+ mouse showed
a marked decrease in hepatic triglyceride (TG) content and an
improvement of fatty liver compared to equivalent mice lacking
the Cre transgene (ob/ob-PPARg/Cre) (Matsusue et al.,
2003). These results strongly suggest that PPARg is capable of
activating the expression of genes involved in TG accumulation
in hepatocytes and promoting the generation of fatty liver. How-
ever, the molecular mechanism and downstream target genes of
hepatic PPARg associated with hepatic steatosis remain largely
unknown.
To enhance the current understanding of the mechanism of
PPARg-dependent fatty liver formation, we performed studies
to identify downstream target genes of hepatic PPARg by use
of subtractive cDNA cloning between ob/ob-PPARg/Cre and
Cre+ livers. Fat-specific protein 27 (Fsp27) was identified as a
fatty liver-specific gene and a direct downstream target gene of
hepatic PPARg. In addition, forced expression of FSP27 by ade-
novirus in hepatocytes in vivo and in vitro resulted in an increase
in lipid droplets through elevation of TG levels, while knockdown
of FSP27 in ob/ob mice resulted in loss of hepatic lipid.
RESULTS
Subtraction Screening Identifies Hepatic PPARg
Targets
To identify direct transcriptional targets of hepatic PPARg in
ob/ob mouse fatty liver, a subtractive cloning strategy was used
that takes advantageof the availability of the liver-specificPPARg
null mouse and the specificity provided by the synthetic PPARg
ligand rosiglitazone. RNA from ob/ob-PPARg/Cre and Cre+
livers was used to create a subtracted cDNA library, and after ac-
counting for redundancy, only three cDNAs were identified from
the screening as being specifically expressed in ob/ob mouse
fatty liver: stearoyl-CoA desaturase 1 (Scd1), fat-specific protein
27 (Fsp27), and cell death-inducing DFFA-like effector a (Cide a).
A decrease in SCD1mRNA in PPARg null ob/ob liver has been
demonstrated previously (Matsusue et al., 2003). The Cide a and
Fsp27 genes are members of the CIDE family (Lin and Li, 2004).
Rat Cide a was originally identified as a gene encoding a protein
with homology to the N-terminal region of DNA fragmentation
factor 45 (DFF45). Overexpression of CIDE A in 293T cells leads
to enhanced apoptosis (Inohara et al., 1998). Independently,
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differentiated mouse adipocyte cell line TA1 (Danesch et al.,
1992; Williams et al., 1992). The human ortholog of Fsp27, re-
ferred to as CIDE 3, also induces apoptosis (Liang et al., 2003).
To determine the molecular mechanism for development of
PPARg-dependent hepatic steatosis, the physiological role of
the Cide a and Fsp27 gene products in fatty liver was examined.
Hepatic Steatosis and PPARg-Dependent Expression
of Cide a and Fsp27
ThemouseCIDE family is composed of three genes,Cide a,Cide
b, and Fsp27 (Inohara et al., 1998; Liang et al., 2003). The expres-
sion of these genes in ob/ob-PPARg/Cre and ob/ob-PPARg/
Cre+ mouse livers was confirmed by northern blotting (Figure 1).
Expression ofCIDEAandFSP27mRNAswasobserved inob/ob-
PPARg/Cre liver. However, they were expressed at markedly
lower levels in ob/ob-PPARg/Cre+ liver and were not detectable
in OB/OB-PPARg/Cre and OB/OB-PPARg/Cre+ livers from
a normal genetic background. Rosiglitazone treatment induced
the expression of CIDE A and FSP27 mRNAs in ob/ob-PPARg/
Cre mouse liver, but not in ob/ob-PPARg/Cre+ mouse liver. In
contrast to the selective expression of the Cide a and Fsp27
genes, the Cide b gene was highly expressed in livers of all
mouse lines examined, with no response to the hepatic PPARg
deficiency or rosiglitazone treatment noted. Since hepatic stea-
tosis develops on the ob/ob-PPARg/Cre mouse background
and is improved by disrupting PPARg expression in this tissue,
these results indicate that expression of the Cide a and Fsp27
genes is hepatic PPARg dependent and positively correlated
with development of hepatic steatosis.
CIDE A and FSP27 Expression in ob/obMouse Liver
The Cide a and Fsp27 genes are highly expressed in ob/ob-
PPARg/Cre liver, but not in ob/ob-PPARg/Cre+ liver (Figure 1).
An earlier report demonstrated that overexpression of rat CIDE A
in a cell line induces apoptosis (Inohara et al., 1998). Thus, to com-
pare apoptosis between ob/ob-PPARg/Cre and ob/ob-PPARg/
Cre+ livers, TUNEL assay was performed in liver sections from
both typesofmice.However, nosignificantdifference inapoptosis
was observed between ob/ob-PPARg/Cre and ob/ob-PPARg/
Cre+ mouse livers (data not shown). These results suggest that
theCide a and Fsp27 gene products expressed in hepatic steato-
sis have a physiological function in liver independent of apoptosis.
Expression Pattern of Cide a and Fsp27
To determine the tissue-specific expression of the Cide a and
Fsp27 genes, CIDE A and FSP27 mRNAs were measured in
ob/ob-PPARg/Cre and ob/ob-PPARg/Cre+ mice (see Fig-
ure S1A available online). In addition to expression in the liver
(LI), expression of the Cide a gene was specifically observed in
brown adipose (BA) and was slightly induced in white adipose
(W) by administration of rosiglitazone. The Fsp27 gene was
highly expressed in brown adipose, white adipose, and liver
and was expressed at lower levels in lung (L) and colon (C). Ro-
siglitazone also induced FSP27 mRNA in these tissues. Expres-
sion of the Cide b gene was observed in kidney (K), liver, and
colon and was unchanged by rosiglitazone.
Fsp27was also expressed in fully differentiated 3T3-L1 adipo-
cytes in which PPARg is highly expressed and induced byrosiglitazone treatment (Figure S1B). Furthermore, infection of
mouse primary hepatocytes with an adenoviral vector express-
ing PPARg induced mRNA for not only FSP27 but also aP2,
which is a known PPARg target (Figure S1C). It is noteworthy
that expression ofCide awas not observed under the same con-
ditions under which Fsp27 and PPARg were expressed. These
data suggest that the transcriptional mechanism ofCide a differs
from that of Fsp27.
Brown adipose tissue also expressed both Cide a and Fsp27
(Figure S1A). Thus, mouse primary brown adipocytes were
used to further characterize expression of Cide a and Fsp27.
Consistent with earlier reports (Zhou et al., 2003), expression
of Cide a depended on the differentiation of adipocytes and
was markedly decreased by the addition of TNFa. Although
Fsp27 also showed differentiation-dependent expression, its
expression was less sensitive to TNFa (Figure S2).
A Functional Peroxisome Proliferator Response
Element in the Fsp27 Promoter
Expression of the Fsp27 gene was correlated with the expres-
sion pattern of PPARg (Figure 1). However, expression of the
Cide a gene was not correlated with PPARg expression, sug-
gesting the possibility of indirect regulation by PPARg. Thus,
transcriptional regulation of Fsp27 through PPARg was investi-
gated. By searching the MOTIF database (http://motif.genome.
jp/), a putative peroxisome proliferator response element
(PPRE) site in the promoter region of Fsp27 was revealed at po-
sition 214/202 from the transcriptional start site (–1). Putative
binding sites for other transcription factors in the 50 upstream re-
gion of Fsp27 were also identified as HNF-3, GATA3, SREBP-1,
CREBP, and C/EBP. To elucidate whether the Fsp27 gene PPRE
is functional, reporter gene transfection studies were carried out.
Activity of the luciferase reporter constructs D1 and D2 was in-
duced by the addition of rosiglitazone, whereas constructs D3
and D4, which lacked the PPRE, completely lost the induction
of activity by rosiglitazone (Figure 2A). Point mutations (mut1
and mut2) introduced into the PPRE in the D2 construct resulted
in the loss of activation by rosiglitazone (Figure 2B). To assess
whether the luciferase construct including Fsp27-PPRE is also
activated by other PPAR isoforms, PPARa and PPARb were
transfected with or without their respective specific ligands
Figure 1. Expression of Cide a and Fsp27 Genes, but Not Cide b,
Depends on Hepatic PPARg and Fatty Liver Formation
Northern blot analysis was performed on total RNA (10 mg) from two mice.
Rosiglitazone (3 mg/kg/day) was administered to mice for 3 weeks. Control,
diet without rosiglitazone; RGZ, diet containing rosiglitazone; OB/OB, normal
genetic background mice; ob/ob; leptin-deficient mice.Cell Metabolism 7, 302–311, April 2008 ª2008 Elsevier Inc. 303
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Peroxisome Proliferator Response Element
in the Mouse Fsp27 Promoter
(A) Ligand-activated PPARg induces the promoter
activity of the Fsp27 gene through a putative per-
oxisome proliferator response element (PPRE).
HEK293 cells were transfected with serially de-
leted Fsp27 luciferase reporter plasmids and
a pSG-PPARg expression vector. Six hours after
transfection, the medium was exchanged with
fresh medium containing 1 mM rosiglitazone or
DMSO. Cells were harvested 48 hr after transfec-
tion, and luciferase activity was measured.
(B) HEK293 cells were transfected with reporter
plasmids containing a point mutation of a putative
PPRE sequence in the Fsp27 promoter. In the
mut1 and mut2 plasmids, a cytosine base (bold)
was replaced by an adenine base (bold) in the
putative PPRE sequence in the D2 plasmid as
indicated in the upper panel.
(C) PPARg-specific activation of Fsp27 promoter
activity. HEK293 cells were transfected with the
thymidine kinase (TK) promoter including the con-
sensus PPRE sequence promoter as a positive
control or Fsp27 promoter luciferase plasmids
(D2 plasmid in [A]) and each PPAR isoform expres-
sion vector. Six hours after transfection, the cells
were treated with specific ligand: PPARa, 50 mM
Wy-14643; PPARb, 0.5 mM L-165041; PPARg,
1mM rosiglitazone.
Data are mean ± SEM from three independent
experiments. *p < 0.05, **p < 0.01, ***p < 0.001
versus control without ligand.Wy-14643 and L-165041 (Figure 2C). The luciferase activity of
a positive control construct driven by the thymidine kinase pro-
moter including the consensus PPRE was markedly induced
by these ligands in the presence of each PPAR isoform (Fig-
ure 2C, left panel). However, under the same conditions, PPARa
and PPARb could not induce the activity of the Fsp27-PPRE,
while PPARg significantly induced the activity of this construct
(Figure 2C, right panel). These results suggest that the PPRE
(214/202) identified on the Fsp27 promoter is a functional
and PPARg-specific cis-element.
Endogenous Adipocyte or Fatty Liver PPARg Directly
Interacts with the Fsp27-PPRE
To demonstrate additional evidence for direct regulation by
PPARg, an electrophoretic mobility shift assay (EMSA) using
Fsp27-PPRE as probe was performed (Figure S3). PPARa/
RXRa or PPARg/RXRa heterodimers formed when the consen-
sus PPRE probe was used. Similarly, the aP2-PPRE probe was
observed to bind with both PPARs/RXRa heterodimers under
these conditions. The RXRa/RXRa homodimers could also
bind to these probes (Vivat-Hannah et al., 2003). Interestingly,
PPARg/RXRa heterodimers could bind strongly to the Fsp27-
PPRE probe, while the PPARa/RXRa heterodimers exhibited
much weaker binding. These results suggest that PPARg can
directly bind to the Fsp27-PPRE, and the binding is likely to be
of high affinity for PPARg as supported by the data in Figure 2C.
To demonstrate an interaction between endogenous PPARg
and Fsp27-PPRE under physiological conditions, a chromatin
immunoprecipitation (ChIP) assay was performed with chroma-304 Cell Metabolism 7, 302–311, April 2008 ª2008 Elsevier Inc.tin from 3T3-L1 adipocytes. Three primer sets were designed
to amplify Fsp27-PPRE, non-PPRE as a negative control (Fig-
ure 3A), and aP2-PPRE as a positive control. The results revealed
an association of endogenous PPARg with the Fsp27- and aP2-
PPREs, but not with the non-PPRE. No difference in association
was observed with or without rosiglitazone (Figure 3B). Next,
chromatin from ob/obmouse liver was subjected to ChIP assay.
The PPARg protein expressed in ob/ob fatty liver clearly bound
to the Fsp27-PPRE, although weak background amplification
of the non-PPRE was observed (Figure 3C). Thus, these results
suggest that endogenous PPARg can also bind to Fsp27-
PPRE in both mature adipocytes and ob/ob mouse liver.
Overexpression of FSP27 Leads to Triglyceride
Accumulation
To elucidate the physiological function of Fsp27 andCide a gene
products, adenoviral vectors expressing hemagglutinin (HA)-
tagged FSP27 (AdFSP27) and CIDE A (AdCIDE A) proteins
were generated. The expression of proteins with the expected
molecular size was verified in each adenovirus-infected hepato-
cyte (Figure 4A). On examination by phase-contrast microscopy,
the morphological differences between AdLacZ- and AdFSP27-
infected hepatocytes were obvious. AdFSP27-infected hepato-
cytes exhibited numerous round vacuoles in the cytosolic frac-
tion within approximately 2 days after infection. Furthermore,
oil red O staining revealed fat accumulation in these vacuoles
as lipid droplets (LDs; Figure 4B). The LDs of AdPPARg-infected
hepatocytes were much smaller and fewer in number than those
seen in AdFSP27-infected hepatocytes. Although AdCIDE
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appears to be background as compared with that of AdLacZ-in-
fected hepatocytes. In support of the staining results, TG content
in AdFSP27- and AdPPARg-infected hepatocytes was 150%
and 130% of AdLacZ-infected hepatocytes (Figure 4C), res-
pectively. No significant difference in cholesterol content was
observed between AdLacZ- and AdFSP27- or AdPPARg-in-
fected hepatocytes.
Previous data indicated that hepatic TG levels in ob/ob-
PPARg/Cre+ mice are considerably lower than in ob/ob-
PPARg/Cre mice (Matsusue et al., 2003). In the present study,
the FSP27 mRNA level in ob/ob-PPARg/Cre+ mouse liver was
also observed to be lower (Figure 1). Thus, to confirm whether
the decrease in FSP27 expression is associated with de-
creased TG levels in ob/ob-PPARg/Cre+ liver, an FSP27 rescue
experiment with AdFSP27 injected intravenously into ob/ob-
PPARg/Cre+ mice was performed. Histological analysis re-
vealed few vacuoles in ob/ob-PPARg/Cre+ mouse liver infected
with AdLacZ (Figure 5A), while injection of AdFSP27 led to the
occurrence of numerous vacuoles (Figure 5B). However, these
vacuoles were smaller than those observed in ob/ob-PPARg/
Cre mouse liver (Figure 5C). Expression of HA-tagged
FSP27 or LacZ protein in these livers was verified by western
blot using HA antibody (Figure 5D). Note that in the absence
Figure 3. Endogenous PPARg Associates with Fsp27-PPRE
(A) The positions of primers (arrows) relative to the PPRE of the Fsp27 pro-
moter are shown. The PPRE located in the Fsp27 promoter was amplified by
the primer sets F1 and R1 (Fsp27-PPRE). As a positive control for a bona
fide PPRE, the aP2 gene PPRE (aP2-PPRE) was used. Primer sets F2 and
R2, located >6 kb upstream of the Fsp27-PPRE (non-PPRE), were also used
as a negative control.
(B) Endogenous PPARg in 3T3-L1 adipocytes binds to Fsp27-PPRE. Fully dif-
ferentiated adipocytes were cultured with or without 1 mM rosiglitazone (RGZ)
for 48 hr, and the soluble chromatin from the cells was prepared as described
in Experimental Procedures. IgG, rabbit control IgG; PPARg, rabbit anti-
PPARg IgG.
(C) Endogenous PPARg in ob/obmouse liver binds to Fsp27-PPRE. Input lane
represents genomic DNA from the chromatin before immunoprecipitation
used as the positive control for PCR.of a suitable specific antibody against FSP27, we cannot
precisely estimate the levels of expression of FSP27 protein
produced from the recombinant adenovirus and thus cannot
determine whether the levels obtained reflect the levels found
in livers of ob/ob mice.
Figure 4. Overexpression of FSP27 Protein in Mouse Primary Hepa-
tocytes Leads to Triglyceride Accumulation
(A) Verification of hemagglutinin (HA)-fused proteins expressed by recombi-
nant adenoviral vectors in mouse primary hepatocytes. Hepatocytes from
C57BL/6 mice were infected with AdFSP27, AdCIDE A, AdPPARg, and
AdLacZ at 500 multiplicity of infection (moi). Two days after infection, lysates
from each hepatocyte were subjected to western blot analysis using HA anti-
body.
(B) Oil red O staining of adenovirus-infected hepatocytes. Hepatocytes from
C57BL/6 mice were infected with AdFSP27, AdCIDE A, AdPPARg, and
AdLacZ at 500 moi. Three days after infection, each hepatocyte was stained
with Oil red O. Nuclei were also counterstained with hematoxylin.
(C) Total triglyceride and cholesterol content in adenovirus-infected hepato-
cytes. The infection condition is the same as described above. Data are
mean ± SEM from three independent experiments. *p < 0.05, **p < 0.01 versus
AdLacZ-infected hepatocytes.Cell Metabolism 7, 302–311, April 2008 ª2008 Elsevier Inc. 305
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was 21% of that of ob/ob-PPARg/Cre liver, but AdFSP27-
infected ob/ob-PPARg/Cre+ liver exhibited partial recovery of
hepatic TG (40% of ob/ob-PPARg/Cre liver) (Figure 5E). These
results strongly suggest that the expression of FSP27 leads to
promotion of the formation of intracellular LDs through TG accu-
mulation in hepatocytes in vitro and in vivo.
Knockdown of FSP27 Partially Improves ob/ob Hepatic
Steatosis
To determine the in vivo hepatic function of FSP27, a recombi-
nant adenovirus expressing a short hairpin RNA (shRNA) target-
ing FSP27 was generated. An efficient shRNA sequence for
silencing FSP27-HA protein expression was selected from three
candidates (Figure 6A). Since construct 2 (lane 3) almost com-
pletely repressed FSP27-HA protein expression, it was used
for the generation of the recombinant adenovirus shRNA. The
adenovirus expressing FSP27 shRNA (AdshFSP27) and an ade-
novirus expressing control scrambled shRNA (Adshscram) were
used to infect 3T3-L1 adipocytes, which constitutively express
FSP27 (Figure 6B). Although adenovirus is known to have low
transduction efficiency for adipocytes, AdshFSP27 dramatically
decreased FSP27 mRNA by 35% at an 8000multiplicity of infec-
tion (moi) as compared with Adshscram, indicating that the gen-
erated AdshFSP27 is functional for knockdown of native FSP27.
Figure 5. Overexpression of FSP27 Protein in ob/ob
Liver Lacking PPARg Restores Triglyceride Accumu-
lation
(A–C) ob/ob-PPARg/Cre+ mice were treated with pioglitazone
for 3 weeks, injected with AdLacZ (A) or AdFSP27 (B), and
maintained on 0.01% pioglitazone for another 6 days. ob/ob-
PPARg/Cremice were treated similarly with pioglitazone and
without adenovirus infection as a positive control (C).
Hematoxylin and eosin (H&E) staining was performed on liver
sections from each mouse line/treatment. The AdFSP27-
infected ob/ob-PPARg/Cre+ mice exhibited fatty liver, as
revealed by vacuolated hepatocytes (B), while the livers of
AdLacZ-infected ob/ob-PPARg/Cre+ mice remained un-
changed (A).
(D) Verification of LacZ-HA and FSP27-HA proteins expressed
by recombinant adenoviral vectors in ob/ob-PPARg/Cre+
mouse liver. Cell lysates from livers as shown above were sub-
jected to western blot analysis using HA antibody. Lysates
from HEK293 cells infected with AdLacZ and AdFSP27 were
used as positive control.
(E) Livers from mice as shown above were also used for mea-
surement of hepatic triglyceride content. The number of mice
in each group is as follows: ob/ob-PPARg/Cre = 5 (2 male, 3
female); AdLacZ-infected ob/ob-PPARg/Cre+ = 3 (3 male);
AdFSP27-infected ob/ob-PPARg/Cre+ = 4 (4 male). Data are
mean ± SEM. *p < 0.01 versus AdLacZ-infected hepatocytes.
Therefore, AdshFSP27 or Adshscram was used to
infect ob/ob-PPARg/Cre mice (Figure 6C). Liver
sections from Adshscram-infected ob/ob-PPARg/
Cre mice revealed the presence of numerous
large hepatocyte vacuoles. Interestingly, the va-
cuoles in hepatocytes around the large vein in
AdshFSP27-infected liver were clearly smaller
and less numerous than those in hepatocytes
remote from the vein (arrows), although some vacuoles still
remained. AdshFSP27 dramatically decreased FSP27 mRNA in
ob/ob-PPARg/Cre mouse livers by 90% as compared with
Adshscram, indicating that the generated AdshFSP27 is func-
tional for knockdown of native FSP27 (Figure 6D). The TG con-
tent of AdshFSP27-infected liver showed a tendency toward
lower levels as compared to Adshscram-infected liver, although
the difference was not significant (Figure 6E).
Hepatocyte FSP27 Represses Mitochondrial
b-Oxidation Activity and Decreases Triglyceride
Turnover
To elucidate the mechanism of TG accumulation by FSP27
protein, the metabolic profile of [14C]oleic acid (OA) as a TG pre-
cursor was compared between AdLacZ- and AdFSP27-infected
hepatocytes. OA uptake into hepatocytes, TG export into me-
dium, and de novo TG synthesis from OA were unchanged in
AdLacZ- and AdFSP27-infected hepatocytes (Figures 7A–7C).
However, total b-oxidation activity in AdFSP27-infected hepato-
cytes was significantly decreased by 65% as compared with
AdLacZ-infected hepatocytes (Figure 7D). b-oxidation of fatty
acids in hepatocytes occurs not only in mitochondria but also
in peroxisomes. To distinguish between b-oxidation in mitochon-
dria and in peroxisomes, activity wasmeasured in the absence or
presence of antimycin and rotenone to inhibit mitochondrial306 Cell Metabolism 7, 302–311, April 2008 ª2008 Elsevier Inc.
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Liver Partially Decreases Hepatic Triglyceride
(A) Identification of efficient FSP27 short hairpin RNA (shRNA)
sequences. An FSP27-HA expression plasmid was cotrans-
fected in HEK293 cells with the following plasmids: FSP27
shRNA sequence 1 (lane 2), FSP27 shRNA sequence 2 (lane
3), FSP27 shRNA sequence 3 (lane 4), or control scrambled
sequence (lane 5). Three days after transfection, lysates
were prepared from each cell and subjected to western blot
analysis using HA antibody. The FSP27-HA expression plas-
mid alone (lane 1) and no plasmid (lane 6) were also examined.
(B) Effect of AdshFSP27 on FSP27 mRNA expressed consti-
tutively in 3T3-L1 adipocytes. 3T3-L1 adipocytes were in-
fected with recombinant adenoviruses expressing shRNA
targeting FSP27 (AdshFSP27) or control scrambled shRNA
(Adshscram). Total RNA from each cell infected at different
moi was subjected to northern blot analysis.
(C) H&E staining of liver sections from each mouse line/treat-
ment. ob/ob-PPARg/Cre mice were treated with rosiglita-
zone for 3 weeks and then injected with Adshscram or
AdshFSP27. The mice were maintained on rosiglitazone for
another 7 days.
(D) Effect of AdshFSP27 on FSP27mRNA expressed constitu-
tively in AdshFSP27- and Adshscram-injected livers. Northern
blot analysis was performed on total RNA (10 mg) from each
liver.
(E) Livers as shown above were also used for measurement of
hepatic triglyceride content. The number of mice in each
group is as follows: Adshscram-injected mice = 3 (3 male);
AdshFSP27-injected mice = 4 (4 male). Data are mean ± SEM.b-oxidation (Thomas et al., 1979). FSP27 expressed in hepato-
cytes significantly decreased the activity of mitochondrial b-oxi-
dation (Figure 7E), but not peroxisomal b-oxidation (Figure 7F).
Further, TG turnover as an indicator of intracellular TG accumula-
tion was compared between AdLacZ- and AdFSP27-infected he-
patocytes (Figure 7G). The hepatocytes were first incubated with
[14C]OA/BSA complex for 24 hr to generate a pool of labeled TG.
The supplemental [14C]OA/BSA was removed, and the hepato-
cytes were infected with AdLacZ or AdFSP27 and incubated
with serum-free medium containing triacsin C, a fatty acyl-CoA
synthetase inhibitor, to inhibit further TG synthesis (Tomoda
et al., 1991). The TG content in AdLacZ-infected hepatocytes de-
creased to 70% of control at 24 hr and to 60% of control at 48 hr
from the start of the incubation, while the TG content in FSP27-in-
fected hepatocytes remained almost unchanged at 90% of con-
trol at 24 hr and 100% of control at 48 hr. These results suggest
the possibility that the TG accumulation by FSP27 may be due
to impaired b-oxidation activity and reduced TG turnover.
DISCUSSION
Cide A and Fsp27 Are Fatty Liver-Specific,
PPARg-Dependent Genes
Themain goal of the current studywas to elucidate themolecular
mechanism of PPARg-dependent hepatic steatosis. Although
Cide a and Fsp27 are not novel genes, the present results
demonstrate that they are highly expressed in fatty liver of
ob/ob mice and that expression of both mRNAs, but not the
related CIDE B mRNA, is lost in ob/ob liver lacking PPARg. Inaddition, Cide a and Fsp27 gene expression were not observed
in the liver of normal genetic background mice. PPARg defi-
ciency in ob/ob mouse liver dramatically improves hepatic
steatosis (Matsusue et al., 2003). Therefore, the Cide a and
Fsp27 genes may be directly or indirectly involved in pathways
of steatosis formation.
Fsp27 Is a PPARg Target Gene in ob/ob Hepatic
Steatosis
Analysis by northern blot revealed that expression of the Fsp27
gene was completely restricted to cells or tissues expressing
PPARg and additively induced in the presence of PPARg ligand.
Although Fsp27 expression was also observed in lung and colon,
these tissues also express PPARg in a limited number of cells
(Mansen et al., 1996; Simon et al., 2006). Thus, Fsp27 could be
a direct target gene of hepatic PPARg. Indeed, the present stud-
ies demonstrate a functional PPRE, located at positions 214/
202 from the transcription initiation site of Fsp27, that directly
interacts with PPARg in vitro and in vivo. It is noteworthy that
the reporter assays revealed PPARg-specific activation of pro-
moter activity. Furthermore, the binding affinity of PPARg for
the Fsp27-PPRE was markedly stronger than that of PPARa.
These results suggest that the Fsp27 gene is specifically regu-
lated by PPARg. The finding of a PPARg-specific gene in hepa-
tocytes could explain the loss of the fatty liver phenotype in
ob/ob mouse liver lacking PPARg, which is independent of ex-
pression of PPARa as previously reported (Matsusue et al.,
2003). Thus, the loss of hepatic TG is not solely due to activation
of fatty acid catabolism by PPARa.Cell Metabolism 7, 302–311, April 2008 ª2008 Elsevier Inc. 307
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Hepatocytes Represses Mitochondrial b-
Oxidation Activity and Reduces Triglyceride
Turnover
Mouse primary hepatocytes were incubated with
500 moi of AdLacZ or AdFSP27 for 3 days and
then with [14C]oleic acid (OA)/BSA complexes.
The results in (A)–(F) are normalized by protein
content and displayed as % values of AdLacZ-
infected hepatocytes.
(A) [14C]OA uptake into hepatocytes.
(B) Export of [14C]OA-incorporated triglyceride
(TG) into medium.
(C) TG synthesis from [14C]OA.
(D) Total b-oxidation.
(E) Mitochondrial (Mt) b-oxidation activity.
(F) Peroxisomal (Per) b-oxidation activity. Per b-
oxidation activity was measured in the presence
of 4 mg/ml antimycin and 20 mg/ml rotenone to
inhibit Mt b-oxidation activity.
(G) TG turnover in hepatocytes expressing FSP27.
Mouse primary hepatocytes were incubated with
[14C]OA/BSA complex for 24 hr and then with
500 moi of AdLacZ or AdFSP27 in the presence
of 20 mM triacsin C. The results are normalized
by protein content and displayed as % values of
time 0.
Data are mean ± SEM from three independent
experiments. *p < 0.01, **p < 0.001 versus
AdLacZ-infected hepatocytes.In contrast to Fsp27, the mechanism of regulation of the Cide
a gene remains elusive. Recently, others have demonstrated that
CIDE A mRNA is expressed at high levels following treatment
with PPARa ligands or PPARg overexpression and that the
Cide a promoter contains a functional PPRE responsive to
both of these PPAR isotypes (Viswakarma et al., 2007), thus in-
dicating that it is directly regulated by PPARg. However, the
present studies show that in vitro forced expression of PPARg
in primary mouse hepatocytes induces Fsp27 or the typical
PPARg target gene aP2, but not Cide a. Thus, while it remains
unclear whether theCide a gene is directly or indirectly regulated
by PPARg, the transcriptional regulation of Cide a is clearly
distinct from that of Fsp27.
FSP27 Directly Mediates PPARg-Dependent Hepatic
Steatosis
While themechanisms of hepatic steatosis in ob/obmice are less
clear, it was previously revealed that hepatic PPARg is critical for
lipogenic gene expression and the subsequent development of
fatty liver in ob/ob mice (Matsusue et al., 2003). In the present
study, forced expression of the FSP27 protein in primary hepato-
cytes resulted in an increase in LDs and TG, but not cholesterol
levels. Although the expression of lipidmetabolism-related genes
(fatty acid synthase [Fas], CD36, and adipose differentiation-re-
lated protein [Adrp]) in AdFSP27-infected hepatocytes was
confirmed, therewas no significant difference in TGaccumulation
between AdLacZ- and AdFSP27-infectedwild-typemouse hepa-
tocytes (data not shown). In addition, AdFSP27 infection of308 Cell Metabolism 7, 302–311, April 2008 ª2008 Elsevier Inc.ob/ob-PPARg/Cre+ livers lacking both FSP27 expression and
hepatic steatosis resulted in TG recovery corresponding to 20%
of that observed in ob/ob-PPARg/Cre mouse liver. Therefore,
PPARg-dependent TG and LD accumulation might be due in
part to FSP27 that is induced in ob/ob fatty liver. Elevated
FSP27 mRNA was also observed in fatty liver of high-fat (HF)-
fed normal mice and was additively induced by administration of
pioglitazone (data not shown). This is likely due to PPARg, which
is also induced in HF-fed fatty liver (Inoue et al., 2005). Therefore,
the increased expression of FSP27 is associated with steatosis
formation and is not restricted to the ob/obmouse but is also de-
tected inHF-fed normalmice. It would be interesting to determine
whether TG accumulation by FSP27 requires additional factors
associated with type 2 diabetes or obesity found in ob/obmice.
In support of the data on overexpression of FSP27, FSP27
knockdown by AdshFSP27 causes loss of hepatocyte vacuoles.
In particular, the hepatocytes around the large veins in ob/ob-
PPARg/Cremouse liver revealed a clear loss of vacuoles. Since
AdshFSP27 was intravenously injected in the tail vein, the FSP27
shRNA may be more highly expressed in hepatocytes near the
vein and efficiently decrease FSP27. However, the decreased
TG levels caused by AdshFSP27 infection were not significantly
different from controls. This may be due to inability of the re-
combinant adenovirus to penetrate the whole liver. In addition,
the present study suggests that FSP27 impairs the TG turnover
rate, resulting in accumulation of intracellular TG. Since intracel-
lular TG generally has a lower turnover rate, the influence of the
decreased FSP27 level caused by AdshFSP27 infection appears
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acute adenovirus expression system employed in this study.
While the LD and TG accumulations in AdPPARg-infected he-
patocytes were less than those in AdFSP27-infected hepato-
cytes, overexpression of PPARg also led to induction of FSP27
mRNA by rosiglitazone treatment. Thus, it is likely that FSP27, in-
troduced into the hepatocytes by AdPPARg, is not expressed for
a sufficient length of time in culture to cause a marked accumu-
lation of TG and LDs as is found in liver of ob/obmice. This is due
to the inherently short life span of primary hepatocytes. Indeed,
an earlier report demonstrated that the hepatocyte cell line AML
12, which stably expresses PPARg, exhibits accelerated lipid
accumulation and the expression of lipogenic genes (Schadinger
et al., 2005).
FSP27 Decreases Mitochondrial b-Oxidation Activity
and Triglyceride Turnover
The present study reveals that hepatic FSP27 promotes TG ac-
cumulation by repression of mitochondrial b-oxidation activity or
decreasing TG turnover. Recently, others have demonstrated
that FSP27 depletion in 3T3-L1 adipocytes significantly stimu-
lates lipolysis and reduces the size of LDs, indicating that
FSP27 negatively regulates lipolysis and promotes TG accumu-
lation (Puri et al., 2007). Furthermore, this study revealed that
FSP27 is localized to LDs, and not to mitochondria, in 3T3-L1
adipocytes (Puri et al., 2007). In contrast to these results, other
reports have demonstrated that CIDE A, CIDE B, and CIDE 3
(the human ortholog of FSP27) are localized to mitochondria
(Chen et al., 2000; Liang et al., 2003; Zhou et al., 2003). The rea-
son for these reported differences in the localization of FSP27
remains unclear. The present results reveal that overexpression
of FSP27 in hepatocytes decreases TG turnover in the presence
of triacsin C. Since triacsin C inhibits new TG synthesis (Tomoda
et al., 1991), the decreased turnover is likely to be due to repres-
sion of lipolysis. Therefore, TG accumulation by FSP27 may oc-
cur through the TG protection from constitutive lipolysis. Such
a function is not unique to FSP27; perilipin A localizing to LDs
in adipocytes is also capable of protecting TG from lipolysis
(Brasaemle et al., 2000).
A direct link between impaired b-oxidation and intracellular
TG accumulation is less clear. However, earlier reports have re-
vealed evidence for this association. Mitochondrial trifunctional
protein (MTP) is a complex enzyme that catalyzes the final steps
of mitochondrial b-oxidation. Mtp null mice die 6–36 hr after
birth, coincident with rapid development of hepatic steatosis
(Ibdah et al., 2001). It remains unclear whether and how FSP27
suppresses b-oxidation activity. One possible mechanism may
be that decreased TG turnover might be a secondary cause of
impairment of b-oxidation activity due to lack of fatty acyl-CoA
released from TG. The mechanism by which FSP27 suppresses
b-oxidation will be the subject of future studies.
In a previous report, rosiglitazone markedly exacerbated he-
patic steatosis in ob/ob mice (Matsusue et al., 2003). Thus,
Fsp27 may be the target gene controlling increased steatosis
by rosiglitazone. However, recent studies have demonstrated
that thiazolidinedione derivatives attenuate typical symptoms in
a model of nonalcoholic steatohepatitis (Belfort et al., 2006;
Lang, 2007). Pioglitazone improves hepatic inflammation, de-
creases expression of the fibrogenic genes collagen I andTGF-b1, and decreases hepatic TG levels (Leclercq et al., 2007;
Uto et al., 2005). Thus, the function of PPARg activation in this
model appears to be distinct from the fatty liver models in ob/ob
mice. Notably, it remains unclear whether thiazolidinedione
derivatives directly function in nonalcoholic steatohepatitic liver.
Adiponectin, levels ofwhich are elevatedby thiazolidinediones, is
likely to indirectly improve nonalcoholic steatohepatitis (Tilg and
Hotamisligil, 2006). On the other hand, thiazolidinediones directly
affect ob/ob liver that highly expresses PPARg, resulting in
induction of Fsp27 and the lipogenic effect. Furthermore, the
direct effect of thiazolidinediones may predominate over the
indirect effects of antilipogenic factors such as adiponectin.
More studies are needed to elucidate the effect of thiazolidine-
dione derivatives in the nonalcoholic steatohepatitis model.
In summary, the present study demonstrates a pathway for
hepatic TG accumulation through FSP27. The accumulation sig-
nal is independent of de novo lipogenesis, fatty acid uptake, and
very low-density lipoprotein export, well-known mechanisms for
hepatic TG deposition, and depends on the activation of PPARg.
This finding may extend beyond livers from diabetic leptin-
deficient and HF-fed mice to nonalcoholic fatty liver disease
(NAFLD). Indeed, expression of PPARg is increased in biopsies
of hepatic tissues in patients with NAFLD compared with con-
trols (U. Smith, personal communication). Although expression
of the CIDE 3 (CIDE C) gene, the human ortholog of Fsp27, in
NAFLD has not been determined, the tissue expression profile
retrieved from the GNF SymAtlas database (http://symatlas.
gnf.org/SymAtlas/) closely resembles that of FSP27 as highly ex-
pressed in adipose tissue. Therefore, elucidating themechanism
of the TG-accumulating effects of FSP27 might lead to potential
new therapeutic opportunities for controlling TG accumulation in
NAFLD and its associated pathologies.
EXPERIMENTAL PROCEDURES
Reagents
Rosiglitazone and Wy-14643 were purchased from Alexis Biochemicals and
Sigma-Aldrich, respectively. Pioglitazone and L-165041 were kindly provided
by Takeda Chemical Industries, Ltd. and Merck Research Laboratories,
respectively.
Subtractive Screening
ob/ob-PPARg/Cre+ and Cre mice were administered rosiglitazone for 3
weeks at 3 mg/kg/day (Matsusue et al., 2003). For subtractive screening,
total RNA was isolated from each liver by TRIzol (Invitrogen), and poly(A)
RNAwas prepared from total RNA using theOligotexmRNAMini Kit (QIAGEN).
PCR-based cDNA subtraction was performed using the PCR-Select cDNA
Subtraction Kit (Clontech).
Construction of Expression and Reporter Plasmids
The expression vectors encoding mouse PPARa, PPARb, PPARg, and human
RXRa were described previously (Matsusue et al., 2006). To create recombi-
nant FSP27, CIDE A, and PPARg fusion proteins with HA tags, the open read-
ing frames (ORFs) of mouse Fsp27 and Cide a were amplified by PCR from
ob/obmouse liver cDNA,while the pSGPPARg expression vector was used as
the template for amplification of the PPARg ORF. Each ORF was cloned into
pIRES-hrGFP-2a containing the HA coding region (Stratagene). The following
PCR primer pairs were used: Fsp27, 50-CGGGATCCAAGGATGGACT-30 and
50-GGAATTCGTTGCAGCATCTTCAGAC-30; Cide a, 50-CGGGATCCGAACAA
TGGAGACCGCC-30 and 50-GGAATTCGCATGAACCAGCCTT-30; PPARg, 50-
ACATGCATGCGCCACCATGGTTGACACAGAGAT-30 and 50-CCGCTCGAGC
GGATACAAGTCCTTGTAGA-30.Cell Metabolism 7, 302–311, April 2008 ª2008 Elsevier Inc. 309
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(Danesch et al., 1992). The868 (D1),433 (D2), and194 (D3) bp fragments
from the transcriptional start site (1) of the mouse Fsp27 promoter containing
KpnI and MluI sites in the 50 and 30 end of the primers were amplified by PCR
and cloned into the luciferase reporter vector pGL3-Basic (Promega). Point
mutations were introduced into the putative PPRE site in the D2 construct
by PCR-based site-directedmutagenesis using the following primer pairs (mu-
tations in the putative PPRE site are underlined): mut1, 50-ACGGGAGAACG
TATCACGGTACCCGTCA-30 and 50-GTACCGTGATACGTTCTCCCGTGTCTT
C-30; mut2, 50-GAAGACACGGTAGAACGGATCACGGTAC-30 and 50-GATCC
GTTCTACCGTGTCTTCGTTACC-30.
Northern and Western Blot Analysis
Northern blot analysis was performed as described previously (Matsusue
et al., 2003). The ORF in the FSP27 or CIDE A expression vector was used
as cDNA probe. The cDNA probe for Cide b was amplified by PCR from
a mouse liver cDNA library using gene-specific primers and cloned into
pGEM-T Easy Vector (Promega). The following PCR primer pair was used:
Cide b, 50-GGAGTACCTTTCAGCCTTCAACC-30 and 50-CCTTGGAAATCA
CAGCTCATGG-30. Western blot analysis was also performed as described
previously (Matsusue et al., 2003).
In Vitro Translation and Electrophoretic Mobility Shift Assay
The in vitro translation and electrophoretic mobility shift assay was described
previously (Matsusue et al., 2006). An oligonucleotide probe was synthesized
with the following PPRE (DR1) sequence: Fsp27-PPRE, 50-CTGTGCCCTCT
TGCCTAGTGC-30; aP2-PPRE, 50-CTCTCTGGGTGAAATGTGCATTTCTG-30
(Juge-Aubry et al., 1997) along with an oligonucleotide of complementary
sequence.
Production, Purification, and Infection of Recombinant Adenovirus
Recombinant adenoviruses expressing mouse FSP27, CIDE A, PPARg, and
LacZwere constructed using the Adeno-X Expression System 2Kit (Clontech).
The titer of the adenovirus was determined using the Adeno-X Rapid Titer Kit
(Clontech). Hepatocytes were infected with each adenovirus in serum-free
DMEM/F12 medium for 1 hr at a dose with moi as described in the figure leg-
ends. For in vivo infection, 10- to 12-week-old mice were intravenously
injected in the tail vein with 3 3 1011 infection units of AdLacZ or AdFSP27
in a total volume of 200 ml and killed 6 days later.
Generation and Infection of the Adenovirus Construct Expressing
shRNA against FSP27
The recombinant adenovirus expressing shRNA targeting FSP27 was
constructed using the BLOCK-iT Adenoviral RNAi Expression System (Invitro-
gen). The nucleotide sequence for the shRNA (shRNA) against FSP27 was
designed by BLOCK-iT RNAi Designer (https://rnaidesigner.invitrogen.com/
rnaiexpress/index.jsp). The finally selected sequences were as follows:
Fsp27 forward, 50-CACCGGAAGGTTCGCAAAGGCATCACGAATGATGCCT
TTGCGAACCTTCC-30; Fsp27 reverse, 50-AAAAGGAAGGTTCGCAAAGGCAT
CATTCGTGATGCCTTTGCGAACCTTCC-30; scrambled forward, 50-CACCG
CGCGCTTTGTAGGATTCGCGAACGAATCCTACAAAGCGCGC-30; scrambled
reverse, 50-AAAAGCGCGCTTTGTAGGATTCGTTCGCGAATCCTACAAAGCG
CGC-30. The procedures for production and purification of the recombinant
adenovirus were in accordance with the manufacturer’s instructions.
For in vivo infection of adenovirus shRNA, 10- to 12-week-old ob/ob-
PPARg/Cre mice were first administered rosiglitazone for 3 weeks at
3 mg/kg/day. The mice were then intravenously injected in the tail vein
with 1.2 3 1010 infection units of Adshscram or AdshFSP27 in a total volume
of 400 ml and killed 7 days later.
Chromatin Immunoprecipitation Assay
ChIP assay was performed using a Chromatin Immunoprecipitation Assay Kit
(Upstate) with anti-PPARg antibodies (H-100, Santa Cruz). Fully differentiated
3T3-L1 adipocytes were incubated with or without 1 mM rosiglitazone for 3
days. A ChIP assay was also performed using crude nuclear fractions from
ob/ob mouse liver as described previously (del Castillo-Olivares et al., 2004).
The following PCR primer pairs were used: Fsp27-PPRE forward, 50-CAGAC
CATAAGCCACATCCATTG-30; Fsp27-PPRE reverse, 50-CACAACCCAACAC310 Cell Metabolism 7, 302–311, April 2008 ª2008 Elsevier Inc.TACCCAAGC-30; Fsp27/non-PPRE forward, 50-AAGAATAAGTCGGACCAA
GGTGG-30; Fsp27/non-PPRE reverse, 50-GCAATCGCTCTACTCTGGCAAAG-30;
aP2-PPRE forward (Guan et al., 2005), 50-ATGTCACAGGCATCTTATCCACC-30;
aP2-PPRE reverse, 50-AACCCTGCCAAAGAGACAGAGG-30.
Measurement of Triglyceride Synthesis and b-Oxidation Activity
14C-labeled TG on thin-layer chromatography plates was detected and quan-
tified using a BAS-2000 imaging analyzer (Fuji Photo Film). TG synthesis and
total b-oxidation activity were measured as described previously (Evans
et al., 1992; Linden et al., 2004). Peroxisomal b-oxidation activity was mea-
sured in the presence of 4 mg/ml antimycin and 20 mg/ml rotenone to inhibit
mitochondrial b-oxidation (Linden et al., 2004), while mitochondrial activity
was calculated by subtracting the peroxisomal activity from total activity with-
out antimycin and rotenone. All results are normalized by protein content and
displayed as % values of AdLacZ-infected hepatocytes.
Measurement of Triglyceride Turnover in Hepatocytes
Measurement of TG turnover by [14C]OA/BSA complex was carried out as
described previously (Magnusson et al., 2006). Hepatocytes were seeded at
a density of 5 3 105/well on collagen-coated six-well plates and incubated
with 0.5 mCi/well of [14C]OA/BSA in 1 ml of serum-free DMEM/F12 medium
for 24 hr. After washing two times with PBS, the hepatocytes were infected
with each adenovirus in 500 ml of serum-free DMEM/F12 medium for 1 hr
and incubated with 20 mM triacsin C (BIOMOL), an inhibitor of acyl-CoA
synthetase, to inhibit new TG synthesis. At the indicated times, 14C-labeled
TG was quantified as described above.
Statistics
Experimental values are expressed as mean ± SEM. Statistical analysis was
performed by Student’s t test for unpaired data, with p < 0.05 considered
statistically significant.
SUPPLEMENTAL DATA
Supplemental Data include three figures and can be found with this article
online at http://www.cellmetabolism.org/cgi/content/full/7/4/302/DC1/.
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